NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Fusion Antibodies plc (LSE: FAB)
FAB Technical Analysis
5
As on 25th Apr 2025 FAB SHARE Price closed @ 6.80 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.83 & Strong Buy for SHORT-TERM with Stoploss of 4.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
FABSHARE Price
Open | 6.80 | Change | Price | % |
High | 7.00 | 1 Day | -0.68 | -9.09 |
Low | 6.61 | 1 Week | 0.15 | 2.26 |
Close | 6.80 | 1 Month | -0.10 | -1.45 |
Volume | 602165 | 1 Year | 2.90 | 74.36 |
52 Week High 10.20 | 52 Week Low 2.90 |
LSE UK Most Active Stocks
PREM | 0.04 | 0.00% |
UKOG | 0.01 | 0.00% |
VAST | 0.44 | 0.00% |
TRP | 0.03 | 0.00% |
DEMG | 0.02 | -50.00% |
SEE | 1.75 | 2.94% |
SMDS | 582.50 | 0.00% |
DKE | 0.15 | 0.00% |
SYME | 0.00 | % |
NNN | 0.09 | 50.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
FAB Daily Charts |
FAB Intraday Charts |
Whats New @ Bazaartrend |
FAB Free Analysis |
|
FAB Important Levels Intraday
RESISTANCE | 7.55 |
RESISTANCE | 7.31 |
RESISTANCE | 7.16 |
RESISTANCE | 7.01 |
SUPPORT | 6.59 |
SUPPORT | 6.44 |
SUPPORT | 6.29 |
SUPPORT | 6.05 |
FAB Forecast April 2025
4th UP Forecast | 15.47 |
3rd UP Forecast | 12.69 |
2nd UP Forecast | 10.97 |
1st UP Forecast | 9.25 |
1st DOWN Forecast | 4.35 |
2nd DOWN Forecast | 2.63 |
3rd DOWN Forecast | 0.91 |
4th DOWN Forecast | -1.87 |
FAB Weekly Forecast
4th UP Forecast | 8.42 |
3rd UP Forecast | 7.90 |
2nd UP Forecast | 7.58 |
1st UP Forecast | 7.26 |
1st DOWN Forecast | 6.34 |
2nd DOWN Forecast | 6.02 |
3rd DOWN Forecast | 5.70 |
4th DOWN Forecast | 5.18 |
FAB Forecast2025
4th UP Forecast | 24.1 |
3rd UP Forecast | 18.55 |
2nd UP Forecast | 15.12 |
1st UP Forecast | 11.69 |
1st DOWN Forecast | 1.91 |
2nd DOWN Forecast | -1.52 |
3rd DOWN Forecast | -4.95 |
4th DOWN Forecast | -10.5 |
Fusion Antibodies plc ( LSE UK Symbol : FAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
FAB Other Details
Segment | EQ | |
Market Capital | 31101960.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
FAB Address
![]() |
FAB Latest News
FAB Business Profile
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom. Address: 1 Springbank Road, Belfast, United Kingdom, BT17 0QL
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service